These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 28986504

  • 1. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
    Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Dec; 40(12):1763-1770. PubMed ID: 28986504
    [Abstract] [Full Text] [Related]

  • 2. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED.
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [Abstract] [Full Text] [Related]

  • 3. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 4. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 5. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr 01; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 6. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED, TECOS Study Group.
    Am Heart J; 2020 Jan 01; 219():47-57. PubMed ID: 31707324
    [Abstract] [Full Text] [Related]

  • 7. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Oct 01; 20(10):2379-2388. PubMed ID: 29923323
    [Abstract] [Full Text] [Related]

  • 8. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
    Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2018 Mar 01; 41(3):596-603. PubMed ID: 29311155
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC, Botros FT, Atisso CM, Sager PT.
    Cardiovasc Diabetol; 2016 Feb 24; 15():38. PubMed ID: 26912057
    [Abstract] [Full Text] [Related]

  • 10. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED, TECOS Study Group.
    Am Heart J; 2020 Feb 24; 220():82-88. PubMed ID: 31790905
    [Abstract] [Full Text] [Related]

  • 11. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ, TECOS Study Group.
    Am Heart J; 2019 Dec 24; 218():57-65. PubMed ID: 31707329
    [Abstract] [Full Text] [Related]

  • 12. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep 24; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 13. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
    Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group.
    Circulation; 2017 Sep 26; 136(13):1193-1203. PubMed ID: 28626088
    [Abstract] [Full Text] [Related]

  • 14. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
    McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, Van de Werf F, Green JB, Armstrong PW, Holman RR, TECOS Study Group.
    Eur J Heart Fail; 2020 Nov 26; 22(11):2026-2034. PubMed ID: 32621557
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP, EXAMINE Investigators.
    Diabetes Care; 2016 Jul 26; 39(7):1267-73. PubMed ID: 27289121
    [Abstract] [Full Text] [Related]

  • 16. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
    Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW, TECOS Study Group.
    Diabetes Obes Metab; 2017 Jan 26; 19(1):78-86. PubMed ID: 27607571
    [Abstract] [Full Text] [Related]

  • 17. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ, Paquot N.
    Rev Med Liege; 2015 Oct 26; 70(10):511-6. PubMed ID: 26727841
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR, TECOS Study Group.
    Diabetes Obes Metab; 2018 Jul 26; 20(7):1732-1739. PubMed ID: 29573215
    [Abstract] [Full Text] [Related]

  • 19. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Apr 26; 40(4):494-501. PubMed ID: 28057693
    [Abstract] [Full Text] [Related]

  • 20. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
    Wamil M, McMurray JJV, Scott CAB, Coleman RL, Sun Y, Standl E, Rydén L, Holman RR.
    Diabetes Res Clin Pract; 2020 Dec 26; 170():108488. PubMed ID: 33035598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.